Categories
Change Password!
Reset Password!
Tailored vaccination approaches may be beneficial for immunocompromised groups like systemic lupus erythematosus patients to boost humoral and cellular immunity and reduce the threat of infectious complications.
A randomised study conducted at Seoul National University Hospital revealed that the adjuvanted herpes zoster subunit vaccine is highly effective and safe for patients with systemic lupus erythematosus (SLE).
This study published in ‘The Lancet- Rheumatology’ included patients (aged ≥19 years) with clinically stable SLE and with a history of exposure (more than equal to 4 weeks) to immunosuppressive drugs. They received two doses of the vaccine or intramuscular placebo injection at weeks 0 and 8. Immune responses were evaluated at several points over a year.
Levels of anti-glycoprotein E antibodies and glycoprotein E-specific cell-mediated vaccine responses were assessed at the study's outset, as well as at week 8 post-first dose, and at different time points (weeks 4, 26, and 52) following the second dose. Additionally, the study analyzed reactogenicity along with the SLE disease activity. The main objective was to determine the proportion of patients exhibiting a positive humoral vaccine response four weeks after receiving the second dose.
Study Highlights:
The study supports the vaccine's potential to provide strong protection against shingles in SLE patients, suggestive of the need for larger trials to further validate these promising results.
The Lancet- Rheumatology
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial
Prof Jin Kyun Park et al.
Comments (0)